Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8998203 | Neuropharmacology | 2005 | 8 Pages |
Abstract
Methamphetamine interacts with sigma (Ï) receptors, suggesting that the drug produces some of its physiological and behavioral effects through these sites. Therefore, in the present report, receptor binding and pharmacological studies were performed to characterize the interaction between methamphetamine and Ï receptors. Of the two major Ï receptor subtypes, Ï1 and Ï2, competition binding studies showed that methamphetamine has a 22-fold preferential affinity for the Ï1 subtype. Saturation binding studies using the Ï1 selective radioligand [3H](+)-pentazocine showed that in the presence of methamphetamine, there was a significant change in Kd, but not Bmax, suggesting competitive interactions. In behavioral studies, pretreatment of Swiss Webster mice with the Ï1 receptor antagonists, BD1063 or BD1047, significantly attenuated the locomotor stimulatory effects of methamphetamine. Mice that were administered an antisense oligodeoxynucleotide to down-regulate brain Ï1 receptors also exhibited a reduced locomotor stimulatory response to methamphetamine, as compared to control mice receiving mismatch oligonucleotides. Together, the data suggest that Ï1 receptors are involved in the acute actions of methamphetamine and that antagonism of this subtype is sufficient to prevent the locomotor stimulatory effects of methamphetamine.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Emily C. Nguyen, Kari A. McCracken, Yun Liu, Buddy Pouw, Rae R. Matsumoto,